Valar Labs has developed Vesta, an AI-driven test that predicts patient response to specific cancer therapies, initially focused on BCG treatment for bladder cancer. The system combines a visual AI trained on thousands of histology images with a clinical model tuned to the specific treatment question. The team studied over 1,000 patients across about a dozen medical centers to train and validate the tool, and reports Vesta identifies individuals with triple the normal risk of not responding to BCG. Founders met at Stanford and the company was founded in 2021. Valar emphasizes interpretability so clinicians can see which histological and immune features drive predictions and positions the tool as augmenting—not replacing—pathologists. The company plans to commercialize Vesta, expand to other cancer types, and deploy via a commercial lab model with the goal of insurance coverage to reduce ineffective treatments and costs. Valar Labs is a Palo Alto, CA-based company that applies AI-powered computer vision and digital pathology to improve cancer treatment decision making. The company is building clinical-grade deep learning models to analyze each patient’s characteristics and provide interpretable, actionable insights for oncologists. Its AI is developed with oncologists at the center to enhance clarity during clinical decision making. Valar Labs provides tools aimed at improving cancer care management and related decisions. The company intends to use funding to expand operations and accelerate development efforts.

Total raised

$26M

Funding rounds

2

Latest round

Series A

Latest activity

May 2024